Siddiqui et al. demonstrated that the presence of GNAS in combination with KRAS mutations in pancreatic cystic fluid obtained by EUS-FNA improves the sensitivity for diagnosis of IPMN (accuracy 80%) compared to CEA or KRAS alone [74]. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.